GlassScriptPhysician profile
Joseph Waling
NPI 1114902160
$3,451.55
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,144 · 2020: $558 · 2021: $663 · 2022: $616 · 2023: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $471.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $684.03 | 2019-2022 | |
| Nevro Corp. | $570.29 | 2019-2022 | |
| Medtronic, INC. | $495.46 | 2022-2023 | Intellis Adaptivestim, Vanta Adaptivestim, Synchromedii |
| Abbvie INC. | $325.85 | 2021-2023 | Botox |
| Medtronic USA, INC. | $170.47 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $121.81 | 2019-2021 | |
| Boston Scientific Corporation | $110.83 | 2019 | |
| Stimwave Technologies Incorporated | $108.79 | 2019 | |
| Horizon Therapeutics Plc | $105.11 | 2019-2020 | |
| Abbott Laboratories | $90.74 | 2019-2023 | Proclaim |
| Amgen INC. | $78.05 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.14 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $63.13 | 2019-2020 | |
| Radius Health, INC. | $58.43 | 2022-2023 | Tymlos |
| Tersera Therapeutics LLC | $42.50 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $38.82 | 2019 | |
| Daiichi Sankyo INC. | $36.90 | 2019 | |
| Pfizer INC. | $36.40 | 2019 | |
| Vertos Medical, INC. | $34.71 | 2023 | Mild Device Kit |
| Biodelivery Sciences International, INC. | $29.21 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $24.23 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $24.18 | 2019 | |
| Lilly USA, LLC | $23.32 | 2019-2021 | |
| Averitas Pharma INC. | $19.21 | 2023 | Qutenza |
| Saol Therapeutics INC. | $17.91 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.22 | 2020 | |
| Painteq LLC | $16.39 | 2023 | Painteq |
| Shionogi INC | $15.11 | 2019 | |
| Si-Bone, INC. | $12.06 | 2019 | |
| Pernix Therapeutics Holdings, INC. | $11.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Waling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.